Gyre Therapeutics (GYRE) Capital Expenditures Growth (5y) (2015 - 2025)
Gyre Therapeutics (GYRE) Capital Expenditures Growth (5y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 27.92% |
| Jun 30, 2025 | 74.11% |
| Mar 31, 2025 | 48.31% |
| Dec 31, 2024 | -130.45% |
| Sep 30, 2024 | 269.95% |
| Jun 30, 2024 | 97.06% |
| Mar 31, 2024 | 72.78% |
| Dec 31, 2023 | 67.74% |
| Jun 30, 2023 | 283.14% |
| Mar 31, 2023 | 54.48% |
| Sep 30, 2021 | 86.17% |
| Dec 31, 2018 | 40.28% |
| Jun 30, 2018 | -32.87% |
| Mar 31, 2018 | 23.12% |
| Dec 31, 2017 | -36.58% |
| Mar 31, 2017 | -42.07% |
| Dec 31, 2016 | -13.50% |
| Sep 30, 2016 | -33.33% |
| Jun 30, 2016 | -10.71% |
| Mar 31, 2016 | -31.68% |